Veramyst Side Effects
Generic Name: fluticasone nasal
Note: This page contains side effects data for the generic drug fluticasone nasal. It is possible that some of the dosage forms included below may not apply to the brand name Veramyst.
It is possible that some side effects of Veramyst may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to fluticasone nasal: nasal spray
As well as its needed effects, fluticasone nasal (the active ingredient contained in Veramyst) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking fluticasone nasal, check with your doctor or nurse as soon as possible:More common
- Bloody mucus or unexplained nosebleeds
- shortness of breath
- excessive mucus
- general aches and pains
- loss of appetite
- stomach pain
- runny nose
- White patches inside nose or throat
- blurred vision
- bone fractures
- excess facial hair growth in females
- fullness of face, neck, and trunk
- high blood pressure
- impotence in males
- increased thirst or urination
- lack of menstrual periods
- muscle wasting
Some fluticasone nasal side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common
- Burning, dryness, or other irritation inside the nose
- sore throat
- Runny nose
For Healthcare Professionals
Applies to fluticasone nasal: nasal spray
Endocrine side effects have included suppression of the hypothalamic-pituitary-adrenal axis. The risk of adrenal suppression is less than that associated with systemic corticosteroids and should be of concern only when using higher than recommended doses. Slight suppression of plasma cortisol has been noted following 250 mcg intranasal doses of fluticasone.
Due to extensive first-pass metabolism of fluticasone to an inactive carboxylic acid, significant systemic effects are not expected from any amount of the drug that may be swallowed via intranasal administration of normally recommended dosages. In one study involving 61 patients, no significant difference was demonstrated in the hypothalamic-pituitary-adrenal axis function among patients given intranasal fluticasone 200 mcg/day or placebo for 1 year.
Local side effects have included nasal irritation including burning, dryness, and soreness in 1% to 6% of patients. Nose bleed has been reported in up to 15% of treated patients and sore throat in 2%. Intranasal fluticasone may also cause sneezing. Nasal ulcerations and Candida albicans infections have been reported. Alteration or loss of sense of taste or smell has been reported rarely. Nasal septal perforation and impaired wound healing has also been reported.
Nervous system adverse effects have included headache in 2% to 4% of patients. Some studies have reported headache in as many as 32% of patients. Dizziness has also been reported.
Gastrointestinal side effects have included nausea, vomiting, and dry mouth.
Hypersensitivity side effects have included postmarketing reports of a systemic eosinophilic condition. Clinical features of this condition have included a vasculitis consistent with Churg-Strauss syndrome, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy. These events have usually been associated with a reduction and/or discontinuation of oral corticosteroid therapy following introduction of fluticasone.
Rarely, hypersensitivity reactions have been reported including angioedema, rash, face and tongue edema, pruritus, urticaria, bronchospasm, wheezing, dyspnea and anaphylaxis.
Cases of serious eosinophilic conditions also have been reported with other inhaled corticosteroids in this clinical setting.
Ocular side effects have included reports of cataracts and posterior capsular cataracts.
In 1993, the American Academy of Allergy and Immunology (AAAI) requested that the FDA review its decision regarding the labeled risks of the use of inhaled corticosteroids during severe viral infections. The AAAI's request was based on the lack of data linking inhaled corticosteroids to increases in complications of viral infections.
The danger of infections from immune suppression associated with inhaled corticosteroids has been debated. No conclusive evidence is available to support an increase in tuberculosis or viral infections in patients receiving inhaled fluticasone.
Respiratory side effects have included epistaxis, ulcerations, Candida albicans infection, impaired wound healing, and nasal septal perforation.
More about Veramyst (fluticasone nasal)
- Other brands: Flonase
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.